When it comes to dozens of mps oppose streeting’s new power to say what nhs pays for drugs, dozens of Members of Parliament (MPs) are voicing strong opposition to Health Secretary Wes Streeting's recent decision to grant himself the authority to dictate NHS drug pricing. This move has raised legal concerns and has sparked fears of a significant shift in the way drug costs are determined within the National Health Service (NHS). A total of 31 MPs have signed a motion in the House of Commons that challenges Streeting's ability to override the National Institute for Health and Care Excellence (NICE) guidelines on medication prices.
Critics argue that this decision represents a "power grab" by Streeting, effectively undermining NICE's long-standing role since its establishment in 1999. NICE has been pivotal in assessing the cost-effectiveness of medications, ensuring that NHS resources are allocated to treatments that provide the best value for money. The fear is that giving the Health Secretary the power to dictate pricing could jeopardize the integrity of NICE's evaluations, potentially limiting access to essential medications for patients across England and Wales. Originally reported by The Guardian.
Understanding Dozens Of MPs Oppose Streeting’s New Power To Say What NHS Pays For Drugs
Among those opposing Streeting's new powers are MPs from various political parties, including Labour, the Green Party, the Liberal Democrats, and the Scottish National Party. They have rallied around a "prayer" motion, initiated by former Labour shadow chancellor John McDonnell, which allows MPs to express their discontent with secondary legislation that does not require a direct vote.
This legislative maneuver stems from a statutory instrument that recently empowered Streeting to direct NICE regarding the cost-effectiveness thresholds for health technologies under appraisal. This directive is part of a contentious drug-pricing deal negotiated with the administration of former U.S. President Donald Trump, which has drawn criticism from various quarters.
Concerns Over Pharmaceutical Influence
John McDonnell emphasized that one of NICE's core functions is to protect the NHS from the lobbying power of the pharmaceutical industry. He warned that the current changes, influenced by the U.S. pharmaceutical deal, could significantly undermine NICE's independence. "This risks precious NHS resources being diverted away from life-saving practices and handed to drug companies instead, to the harm of patients," he stated.
Helen Morgan, the Liberal Democrat health spokesperson, echoed McDonnell's sentiments, claiming that the changes were dictated by external pressures from the U.S. government. "This change to NICE rules is clearly coming at the behest of Trump, not because the government thinks it will help patients," she asserted, highlighting the controversial nature of the deal.
Former Health Secretary Joins the Fray
Adding weight to the opposition, former Conservative health secretary Andrew Lansley has also expressed his concerns. As a member of the House of Lords, he introduced a "motion of regret" warning that the new regulations jeopardize NICE's independence and may conflict with the Health and Social Care Act 2012. This Act stipulates that any direction from the Secretary of State should not interfere with NICE's recommendations.
As debates continue, the broader implications of the UK-U.S. drug deal have alarmed health experts. The Health Foundation thinktank cautioned that increased NHS spending on pharmaceuticals may necessitate difficult cuts to other essential health services that offer better value for patients. Economist Eric Yang highlighted the challenges posed by rising demand and demographic changes, stating, "Given worsening funding pressures, the NHS can ill afford to sacrifice resources for a higher drugs bill in the short term."
Criticism from Health Experts and the Medical Community
The ramifications of this deal have not gone unnoticed within the medical community. Kamran Abbasi, the editor-in-chief of the British Medical Journal, criticized the government's approach, arguing that it prioritizes corporate profits over patient welfare. He stated, "The UK taxpayer will end up harming vulnerable people to boost the profits of already obscenely profitable drug companies." These sentiments reflect concerns raised previously by Dr. Samantha Roberts, the former chief executive of NICE, who warned about the potential trade-offs in healthcare spending.
Despite the backlash, the Department of Health and Social Care has defended its position, insisting that the move aims to enhance patient access to innovative treatments. A spokesperson stated, "There is a revolution taking place in medical science, and the secretary of state is determined to secure the fruits of this revolution for many, not just those who can afford to pay." The government claims these changes will ultimately benefit thousands of patients.
As the debate unfolds, the future of NHS drug pricing hangs in the balance. The concerns raised by MPs and health advocates may lead to further scrutiny of the government's approach to healthcare spending and the influence of external pressures on domestic policy.
Originally reported by The Guardian. View original.